Selecting the Right Tool for the Right Job: Which Response Criteria Better Predicts Survival of Patients Treated with Transarterial Radioembolization?

참고문헌 (11)

1. Vincenzi B, "Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with locoregional therapies: a literature-based meta-analysis", PLoS One, 10, pp.e0133488~ (2015)
2. Prajapati HJ, "mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma(HCC)treated by doxorubicin drug-eluting beads transarterial chemoembolization(DEB TACE)", Ann Oncol, 24, pp.965~973 (2013)
3. Gillmore R, "EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization", J Hepatol, 55, pp.1309~1316 (2011)
4. European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
5. Lee Jae Seung, "The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization", Gut and Liver, 14(6), pp.765~774 (2020), 거트앤리버 소화기연관학회협의회[DOI]
6. 주이진, "Imaging Evaluation Following 90Y Radioembolization of Liver Tumors: What Radiologists Should Know", Korean Journal of Radiology, 19(2), pp.209~222 (2018), 대한영상의학회[DOI]
7. Salem R, "Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres : a comprehensive report of long-term outcomes", Gastroenterology, 138, pp.52~64 (2010)
8. Riaz A, "Radioembolization for hepatocellular carcinoma : statistical confirmation of improved survival in responders by landmark analyses", Hepatology, 67, pp.873~883 (2018)
9. Vilgrain V, "Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma(SARAH) : an open-label randomised controlled phase 3 trial", Lancet Oncol, 18, pp.1624~1636 (2017)
10. Chow PKH, "SIRveNIB : selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma", J Clin Oncol, 36, pp.1913~1921 (2018)
11. Seyal AR, "Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma", Hepatology, 62, pp.1111~1121 (2015)

관련 논문AI추천